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Objective: This article aimed to propose a management strategy for cystic neoplasm of the pancreas
based on the available evidence in the medical literature.
Methods: A Medline search was undertaken to identify articles from 1988 to 2008 using the keywords
‘pancreatic cyst’, ‘pancreatic neoplasms’, and ‘cystic neoplasm of pancreas’. Additional papers were
identiﬁed by a manual search of the references from the key articles.
Comments: The optimal management of cystic neoplasms of pancreas remains controversial and should
be individualized based on the balance between the risk and beneﬁt. Multiple factors such as patient’s
comorbidity, performance status, life expectancy, and surgical risk, should be weighed against the
malignant potential of the cyst.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Pancreatic cystic neoplasms are detected more frequently as
a result of increasing use of cross-sectional imaging. Proper
management of this heterogeneous group of tumors is important
because of their high cure rate, as well as frequent confusion with
the much commoner pancreatic pseudocyst. However, cystic
neoplasms of the pancreas present a difﬁcult diagnostic and
treatment problem which stems from: (1) the inability to reliably
diagnose the deﬁnitive type of cystic neoplasm of pancreas; (2) the
inability to distinguish malignant from benign cystic lesions; and
(3) the incomplete understanding of the natural history of cystic
neoplasms of the pancreas.
With an increasing number of patients being identiﬁed with
pancreatic cystic neoplasms, routine resection of all pancreatic
cystic neoplasms is currently impractical. However, the criteria for
a selective approach of management are also not well deﬁned. The
strategies for evaluating and managing patients with pancreatic
cysts are still evolving. Therefore, a thorough understanding of the
characteristics and behavior of each type of cystic neoplasm of the
pancreas is important for the formulation of a proper management
strategy. The goal of management is to identify pre-operatively
those patients with pre-malignant or malignant disease who are
appropriate candidates for pancreatic resection, and avoid the
morbidity and mortality of major operations in asymptomatic
patients with benign disease.
This article aimed to propose a management strategy for cystic
neoplasms of the pancreas based on the available evidence in thex: þ852 2637 7974.
.
ciates Ltd. Published by Elsevier Ltmedical literature. A detailed discussion of each speciﬁc type of
cystic neoplasm of the pancreas is beyond the scope of this article.
2. Methods
A Medline search was undertaken to identify articles from 1988
to 2008 using the keywords ‘pancreatic cyst’, ‘pancreatic
neoplasms’, and ‘cystic neoplasm of pancreas’. Additional papers
were identiﬁed by a manual search of the references from the key
articles.
3. Differential diagnosis of cystic lesions of the pancreas
Although the neoplastic nature of some pancreatic cysts has
been recognized for more than a century, the nomenclature, clas-
siﬁcation and characterization of the various cystic neoplasms of
the pancreas have becomemature only in the last two decades. The
most signiﬁcant recent change in the diagnosis and treatment of
cystic neoplasms of the pancreas is the recognition and description
of the intraductal papillarymucinous neoplasm (IPMN) as a distinct
pathological entity. In 1996, IPMN was classiﬁed by the World
Health Organization (WHO) as distinct from other mucin-
producing cystic neoplasms of the pancreas.
The differential diagnosis of pancreatic cysts and the histological
varieties of cystic neoplasms of the pancreas are shown in Table 1.
Inﬂammatory pancreatic cysts (i.e., pseudocysts) are by far themost
common, accounting for approximately 75% of pancreatic cystic
lesions.1 A pancreatic pseudocyst is a localized collection of
amylase-rich pancreatic secretions, necrotic debris and blood that,
by deﬁnition, has no epithelial lining. The wall of a pseudocyst
consists of ﬁbrin, granulation tissue, and loose ﬁbrotic tissue.d. All rights reserved.
Table 1
Differential diagnosis of cystic lesions of the pancreas
Congenital Simple cyst
Polycystic disease associated with: cystic ﬁbrosis, Von
Hippel–Lindau disease, polycystic disease of the kidney and liver
Enterogenous cyst
Infectious Echinococcal cyst
Inﬂammatory Pseudocyst
Neoplastic Serous cystadenoma
Mucinous cystic neoplasm
Intraductal papillary mucinous neoplasm (IPMN)
Solid pseudopapillary tumor
Lymphoepithelial cyst
Cystic variants of solid neoplasms
Cystic ductal adenocarcinoma
Cystic neuroendocrine tumor
Cystic acinar cell carcinoma
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parenchyma that results in necrosis and autodigestion of pancreatic
tissue from the release and activation of pancreatic enzymes. It
appears as a well-circumscribed, unilocular macrocyst on cross-
sectional imaging.2 A pseudocyst may be indistinguishable from
a cystic neoplasm on imaging studies. The amylase level of
pseudocyst ﬂuid is almost always much higher than the ﬂuid in
cystic neoplasms. The differentiating features of the various cystic
neoplasms of the pancreas are shown in Table 2.3.1. Serous cystadenoma
Serous cystadenoma accounts for 32–39% of pancreatic cystic
neoplasms.3,4 It is a benign neoplasm composed of uniform
cuboidal glycogen-rich epithelial cells, presumably originating
from the centroacinar cell/intercalated duct system and typically
form innumerable small cysts containing serous ﬂuid.5 The sponge-
like gross appearance that gives this tumor the name microcystic
is diagnostic of the entity. Oligocystic (unilocular) serous
cystadenomas have been described, but they are unusual.6,7 TheTable 2
Characteristics of different cystic neoplasms of pancreas
Serous cystadenomas Mucinous cystic neoplas
Sex distribution Female[Male Female[Male
Age group at peak
occurrence
6–7th decade 5–7th decade
Location Evenly distributed Body/tail > Head
Typical imaging feature Central scar or ‘sunburst’
calciﬁcation
Peripheral ‘eggshell’
calciﬁcation
Typical endoscopic
feature
Nil Nil
Gross appearance Well-demarcated, somewhat
bosselated masses, composed
of innumerable small thin-
walled cysts (<1 mm to 2 cm in
diameter), imparting a sponge-
like appearance on cross-
section; oligocystic appearance
less common
Macrocystic appearance
with less than six cysts,
each usually larger than
2 cm in diameter
Communication with
duct
No No
Cyst content Thin straw colored ﬂuid Thick, tenacious mucoid
material
Epithelial lining Glycogen-rich cuboidal
epithelium
Mucin-producing, tall,
columnar epithelium
Stromal characteristics Delicate and vascular to ﬁbrous ‘Ovarian-type’
Malignant potential Extremely low Highﬁbrous stroma separating the cystic areas is relatively vascular and
may calcify, giving rise to the characteristic sunburst, radial or
stellate scar pattern on a computed tomography (CT) scan. When
present, this ﬁnding is diagnostic. However, this typical feature is
present in 13–18% of patients only.8–10 Conﬁrming the diagnosis by
CT can be more challenging in the case of oligocystic lesions, in
which the macrocystic component can appear radiographically
similar to that of inﬂammatory pseudocyst or mucinous cystic
neoplasm. Almost all serous cystadenomas are benign, and the
malignant potential of serous cystadenoma is extremely low.11–15
Serous cystadenomas are also associated with von Hippel–Landau
syndrome (VHL), an autosomal dominant disorder characterized by
hemangioblastomas of the central nervous system and retina, renal
neoplasms and cysts, and pheochromocytomas.163.2. Mucinous cystic neoplasms
Mucinous cystic neoplasms account for 10–45% of pancreatic
cystic neoplasms.3,17 It is a neoplasm composed of mucin-
producing epithelial cells associated with an ovarian-type of
stroma.5,18 These lesionsmay be unilocular or multilocular andmay
contain shaggy, papillary excrescences extending into the lumen of
the cyst. The cystic spaces of this tumor are characteristically larger
than that of serous cystadenoma. Calciﬁcation within the ﬁbrous
capsule of mucinous cystic neoplasms may present in a peripheral
‘eggshell’ pattern on plain X-ray or CT scan. Mucinous cystic
neoplasms represent a spectrum of disease ranging from benign
mucinous cystadenomas to very aggressive invasive mucinous
cystadenocarcinomas. Carcinomatous foci may be patchy and
difﬁcult to discern macroscopically.3.3. Intraductal papillary mucinous neoplasms (IPMN)
IPMN accounts for 21–33% of pancreatic cystic neoplasms.3,19
IPMN is an intraductal papillary mucin-producing neoplasm,
arising in the main pancreatic duct or its major branches. Thems Intraductal papillary mucinous
neoplasms
Solid and pseudopapillary tumors
Male ¼ Female Almost exclusively in female
6–8th decade 2–3rd decade
Head > body/tail Evenly distributed
A diffuse or segmental dilatation of
any portion of the pancreatic ductal
system; a lobulated multilocular
cystic lesion located in the uncinate
process and in contiguity with the
dilated main pancreatic duct
Well-deﬁned, low-attenuation
mass with peripheral enhancement
and complex cystic components
with areas of necrosis and internal
hemorrhage
Mucin can be seen oozing from the
ampulla of Vater
Nil
Ectasia of the main pancreatic duct
or branch ducts; ectactic branch
ducts sometimes appear as
a grapelike cluster of mucin-ﬁlled
structures around the main
pancreatic duct
Soft, tan to redmasses with variable
solid and cystic components with
hemorrhagic changes
Yes No
Mucoid Necrotic/hemorrhagic
Pseudostratiﬁed tall, columnar Uniform cells with nuclear grooves
Fibrosis and atrophy Some hyalinization
Moderate Low
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dilatation, and invasiveness are variable. In addition, IPMN lacks the
ovarian stroma, which is characteristic of a mucinous cystic
neoplasm. IPMN is separated into various categories depending
on the degree of cytoarchitectural atypia that is present: IPMN
adenoma, IPMN borderline, IPMN with carcinoma in situ, and
IPMN with invasive carcinoma. IPMN adenomas, IPMN borderline,
IPMN with carcinoma in situ are considered as non-invasive IPMN.
IPMN with invasive carcinoma is considered as invasive IPMN.
A total of 25–48% of IPMN contain invasive carcinoma.19–25 IPMN is
classiﬁed into those predominantly involving the main pancreatic
duct (main duct type) and those predominantly involving the side
branch of the ductal system (branch duct type) because they have
different tumor biological behavior. Branch duct type IPMN is less
often associated with invasive carcinoma than main duct type
IPMN. However, the difference in the prognosis of the main duct
type and the branch duct type is still a controversial issue.
A number of retrospective studies have been performed to identify
the clinicopathological features that can differentiate malignant
IPMN from benign IPMN. There is still no consensus on this. Based
on these studies, four features suggest malignant IPMN: (1) jaun-
dice; (2) worsening or newonset of diabetesmellitus; (3) main duct
type tumor; and (4) mural nodules.19–25
3.4. Solid pseudopapillary tumor
Solid pseudopapillary tumors account for 5.5–12% of pancreatic
cystic neoplasms.3,26 This typically occurs in young women.
Morphologically, solid pseudopapillary tumors are typically large,
encapsulated lesions, with solid and cystic areas and pseudopa-
pillary patterns seen histologically. This tumor often presents as
a large, multilobular mass composed of homogeneous, ﬂeshy tissue
separated by areas of hemorrhagic and necrotic cystic degenera-
tion.26,27 Tumors are generally surrounded by a ﬁbrous capsule and
appear demarcated from the rest of the pancreas, although inﬁl-
tration into surrounding tissues is not uncommon. Solid pseudo-
papillary tumor generally has a low malignant potential.28,29
4. Diagnosis and investigation
A contrast-enhanced triphasic multidetector CT scan of the
abdomen is fundamental to evaluate patients with a suspected
pancreatic cystic lesion. CT scan is an excellent investigation for
cystic lesions in the pancreas, not only for the initial detection of
a lesion but also for the characterization of such lesions by visual-
ization of the calciﬁcation of the cyst wall, septa, mural nodules,
and features suggestive of pancreatitis.30 The appearance of
a pseudocyst is that of a low-attenuation, unilocular cyst with
accompanying signs of acute or chronic pancreatitis. The presence
of a central scar visualized on CT scan is highly diagnostic of serous
cystadenomas. The uncommon ﬁnding of peripheral ‘eggshell’
calciﬁcation on CT scan is speciﬁc to a mucinous cystic neoplasm
and is highly predictive of malignancy. Magnetic resonance
imaging (MRI) is similar to the CT scan in its ability to show cystic
lesions within the pancreas.31 MRI and magnetic resonance
cholangiopancreatography (MRCP) has the added advantage of
providing better characterization of the morphological features of
a cyst and possibly of showing a communication between the cyst
and the pancreatic duct in IPMN.32,33 Endoscopic retrograde chol-
angiopancreatography (ERCP) is a particularly useful adjunct to the
diagnosis of cystic pancreatic lesions. The ductal abnormalities of
chronic pancreatitis support an inﬂammatory origin of a pancreatic
cyst. ERCP is considered as a standard for the diagnosis of IPMN
also. A bulging papilla with mucin oozing out at the time of the
procedure is pathognomonic of IPMN. However, this is seen only in
about 20% of patients with IPMN.19 Endoscopic ultrasound (EUS)can detect smaller tumors than those currently detectable by CT
scan. However, EUS is confounded by the apparent subjectivity of
its interpretation. The feature of serous cystadenoma in EUS often
demonstrates as a honeycomb appearance or multiple tiny cysts.
The classical features of IPMN in EUS include dilatation of the main
pancreatic duct, hypoechoic thickening of the duct wall, mural
nodules or papillary projections, and pancreatic atrophy. The
technique also permits accurate placement of aspiration needles
into a pancreatic cyst. Aspirated ﬂuid has been evaluated by
cytology and chemical measurements of amylase and tumor
markers.34–36 Characterization of cyst ﬂuid is best used to differ-
entiate those with malignant potential mucinous cysts from serous
cystic neoplasm and pseudocysts. However, a broad range of
sensitivities and speciﬁcities and cutoff values have been reported
for these markers, making interpretation very difﬁcult. Cystic ﬂuid
of mucinous cystic neoplasms has been shown to be rich in car-
cinoembryonic antigen (CEA) and low in amylase, while cystic ﬂuid
of serous cystadenoma has been shown to be low in both CEA and
amylase . In fact, not all cystic lesions of the pancreas require
sampling. In many instances, the diagnosis based on clinical and
radiological ﬁndings is straightforward. On other occasions, even
though a precise diagnosis cannot be reached, the indication for
surgery is deﬁnite, such as in cases of symptomatic cystic
neoplasms of the pancreas. In asymptomatic patients, in patients
with a high surgical risk, and in patients with diagnostic uncer-
tainty, cyst ﬂuid analysis helps to determine the optimal thera-
peutic strategy. However, the beneﬁt of EUS and cyst aspiration
must be balanced against the risk of bleeding, infection, pancrea-
titis and tumor cell spillage. A large prospective study (the
Cooperative Pancreatic Cyst Study), after assessing a large number
of cyst ﬂuid tumor markers, concluded that CEA was most useful.34
Receiver operator curve analysis of the tumor markers demon-
strated that for cyst ﬂuid CEA, the greatest area under the curve
(0.79) for differentiating mucinous vs. non-mucinous cystic lesions
was at an optimal cutoff of 192 ng/ml. The accuracy of CEA (88
of 111, 79%) was signiﬁcantly greater than EUS morphology (57
of 112, 51%) or cytology (64 of 109, 59%). In the pooled analysis of
12 studies by van der Waaij et al., comprising data of 450
patients,35 cysts with an amylase concentration <250 U/l were
serous cystadenoma, mucinous cystadenoma, or mucinous cys-
tadenocarcinoma (sensitivity 44%, speciﬁcity 98%), thus, virtually
excluding pseudocyst. A CEA <5 ng/ml suggested a serous
cystadenoma or pseudocyst (sensitivity 50%, speciﬁcity 95%). A CEA
>800 ng/ml strongly suggested mucinous cystadenoma, or
mucinous cystadenocarcinoma (sensitivity 48%, speciﬁcity 98%).
A carbohydrate-associated antigen (CA) 19-9 <37 U/ml strongly
suggested pseudocyst or serous cystadenoma (sensitivity 19%,
speciﬁcity 98%). Cytological examination revealed malignant cells
in 48% of mucinous cystadenocarcinoma (n ¼ 111). The role of
positron emission tomography (PET) has not been established.
Some authors proposed that [18F]ﬂuorodeoxyglucose (18-FDG)
whole body PET imaging can identify cystic lesions of the pancreas,
both malignant and pre-malignant. Sperti et al. reported a sensi-
tivity and speciﬁcity of PET scan for detecting malignant pancreatic
cystic lesions of 94%.37 However, the corresponding ﬁgures repor-
ted by Mansour et al. were 57 and 85%, respectively.38
5. Management strategy
The management strategy of a suspected pancreatic cystic
neoplasm remains controversial and has not been universally
accepted. This controversy arises because of the inability to diag-
nose a particular type of pancreatic cystic neoplasm accurately and
the limited knowledge of the natural history, particularly small
asymptomatic pancreatic cysts. The decision of whether to observe
with regular surveillance or to operate on these small cystic
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resection of all pancreatic cysts.39,40 These authors argue that
because pre-operative differentiation between benign and malig-
nant lesions is unreliable, and because the potential adverse
consequences of non-resectional therapy are signiﬁcant, all medi-
cally ﬁt patients should undergo resection. Although this approach
provides a guarantee to patients that no pre-malignant or malig-
nant lesions be observed, it exposes patients with benign lesions to
the risks of operation with unclear beneﬁt. Some institutions are
now reporting a selective approach to resection in patients who
have small, incidentally discovered cysts of the pancreas.41–44
Factors analyzed as potential predictors of neoplasia included age,
imaging features, cyst size, and symptoms.41–48 Selected asymp-
tomatic patients with cystic lesions less than or equal to 3 cm in
diameter and without a solid component may be followed radio-
graphically, with a malignancy risk that approximates the risk of
mortality from resection. The chance of malignancy was reported
as 3–3.3% in a small number of studies.41,42 There are still no
consensus on the selective criteria used.
The approach in a patient with a pancreatic cystic lesion begins
with a detailed history to deﬁne prior pancreatitis or abdominal
trauma. Pseudocysts are by far the most common cystic lesions. In
most instances, pseudocysts can be distinguished from cystic
neoplasms based on clinical history, biochemical investigations and
cross-sectional imaging appearance, although patients with cystic
neoplasms may also present with pancreatitis. Once a pancreatic
pseudocyst has been excluded, attention should be paid to differ-
entiate between the various types of cystic neoplasms. The most
important diagnosis is to differentiate between mucinous and non-
mucinous cystic lesions because of their different potential of
malignancy. Currently, no single test can accurately make this
distinction, and diagnosis depends on a combination of factors,
including the clinical features, the biochemical and the imaging
ﬁndings. Age, comorbidity, performance status, life expectancy and
symptoms should be considered before pursuing an aggressive
diagnostic workup or surgical management plan. The risk of
surgery should be weighed against the symptoms and the risk of
malignancy. The risk of surgery varies with the location of the
lesion. Lesions in the tail or body of the pancreas can be treated
with a distal pancreatectomy which is associated with much less
morbidity andmortality than pancreaticoduodenectomy for lesions
in the head of the pancreas. If serous cystadenoma cannot
conﬁdently be distinguished from mucinous cystic neoplasm or
IPMN, resection is recommended for patients considered to be an
acceptable surgical risk. When the diagnosis of serous cystadenoma
is conﬁdently determined based on clinical and radiographic
evidence, only symptomatic tumors should be resected. If a deci-
sion is made not to carry out resection initially, serial imaging at
a 6–12-month intervals, with resection for growth or the devel-
opment of symptoms is recommended. In patients with a poor
surgical risk, or in a moribund state, interval cross-sectional
imaging is unnecessary.
Complete resection is generally considered curative for serous
cystadenoma, mucinous cystic neoplasm and solid pseudopapillary
tumor, and post-operative long-term monitoring is rarely neces-
sary. Regular surveillance for disease recurrence is important after
resection for IPMN as there is a risk of recurrence in both non-
invasive and invasive IPMN, and repeat resection for an isolated
recurrence in the pancreatic remnant gives good results. A regimen
consisting of a yearly CT scan or MRI is most widely used for
surveillance after resection of IPMN.19 However, the most effective
method of surveillance, its frequency and the group of patients who
would beneﬁt most from monitoring remains unknown.
In conclusion, the balance between the risk and beneﬁt for
a patient is important in the management of cystic neoplasms of
the pancreas. The threshold of surgery may be lower in those highvolume surgical centers for pancreatic surgery. A management
strategy has been proposed based on the available evidence in the
medical literature. However, the management of cystic neoplasm of
the pancreas is still evolving.Conﬂict of interest
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